IU team studying NF1 receives renewal for $11.4M SPORE

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

An Indiana University research team led by Wade Clapp received renewal for an $11.4 million SPORE grant first awarded by NCI in 2015, supporting research into identifying new treatments for tumors that develop in neurofibromatosis type 1 (NF1), the most common inherited syndrome causing a predisposition to cancer. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Two Republican leaders in the House of Representatives have published a “framework” for reforming NIH—consolidating the agency’s 27 institutes and centers into 15—arguing that a fundamental rethinking of NIH’s structure would fix what they describe as a “system rife with stagnant leadership, as well as research duplication, gaps, and misconduct.”

Login